{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-126489","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.571909+00:00","generated_at":"2026-06-21T05:39:31.343644+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Priveterra (PMGM) enters definitive merger with AEON Biopharma at $165M equity value","bullets":["Implied AEON equity value of $165M; AEON stockholders to receive Priveterra Class A common shares.","Up to 16M earnout shares tied to FDA milestones: Phase 3 migraine start, BLA acceptance for cervical dystonia and migraine.","Bridge financing: up to $20M from AEON stockholders; $4M bridge if Closing not by March 1, 2023; $8M sponsor bridge if S-4 not effective by April 1, 2023.","Closing condition: minimum $45M available cash after redemptions, stockholder approvals, Nasdaq listing, and HSR clearance.","Sponsor (3.45M Contingent Founder Shares) and AEON stockholders subject to 1-year lock-up; early release at $12.50/$15.00 VWAP thresholds."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-126489","json":"https://secwatch.observer/filing/0001104659-22-126489.json","markdown":"https://secwatch.observer/filing/0001104659-22-126489.md","text":"https://secwatch.observer/filing/0001104659-22-126489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/0001104659-22-126489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/tm2232428d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:39:31.343644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a2e2964fd011a39c2f053685bd5ed8bc293bd2e","claim":"AEON Biopharma, Inc. entered into Business Combination Agreement with AEON Biopharma, Inc. valued at implied AEON equity value of $165,000,000, plus up to 16,000,000 earnout shares of Class A common st (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, Priveterra Acquisition Corp., a Delaware corporation (the “ Company ” or “ Priveterra ”), entered into a business combination agreement (the “ Business Combination Agreement ”) by and among the Company, Priveterra Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), and AEON Biopharma, Inc., a Delaware corporation (“ AEON ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000110465922126489/0001104659-22-126489-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"AEON Biopharma, Inc."},{"label":"Value","value":"implied AEON equity value of $165,000,000, plus up to 16,000,000 earnout shares of Class A common st"},{"label":"Effective","value":"2022-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}